Biomarkers in the clinical development of asthma therapies

Here we review how biomarkers have been used in the design, execution and interpretation of recent clinical studies of therapeutic candidates targeting cytokine-mediated inflammatory pathways in asthma. This review focuses on type 2 inflammation, as there are multiple therapeutics and/or clinical st...

Full description

Saved in:
Bibliographic Details
Published in:Biomarkers in medicine 2016-02, Vol.10 (2), p.165-176
Main Authors: Staton, Tracy L, Choy, David F, Arron, Joseph R
Format: Article
Language:English
Subjects:
Allergens
AMG 317
Anti-Asthmatic Agents - therapeutic use
Antibodies, Monoclonal - therapeutic use
Asthma
Asthma - drug therapy
benralizumab
Biomarkers
Biomarkers, Pharmacological - blood
brodalumab
Clinical trials
Clinical Trials, Phase II as Topic
Comparative analysis
Cytokines
Drug dosages
dupilumab
eosinophils
FeNO
golilumab
GSK679586
Humans
Immunotherapy
Inflammation
Inflammation - metabolism
Interleukins - metabolism
lebrikizumab
mepolizumab
Molecular Targeted Therapy
Monoclonal antibodies
omalizumab
patient selection
Patients
periostin
Pharmacodynamics
reslizumab
Signal Transduction
Success
tralokinumab
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here we review how biomarkers have been used in the design, execution and interpretation of recent clinical studies of therapeutic candidates targeting cytokine-mediated inflammatory pathways in asthma. This review focuses on type 2 inflammation, as there are multiple therapeutics and/or clinical studies that can be compared within that specific pathway. Comparative analyses of data from these clinical studies illustrate the utility of biomarkers to quantify pharmacodynamic effects, clarify mechanism of action and stratify patients, which may facilitate the interpretation of outcomes in the development of molecularly targeted therapies. These case examples provide a basis for biomarker considerations in the design of future studies in the asthma setting.
ISSN:1752-0363
1752-0371
DOI:10.2217/bmm.15.116